Therapeutic Apheresis and Human Monoclonal Antibodies in Non-Immunologic Diseases.
TA, HMA in Non-Immunologic Diseases
DOI:
https://doi.org/10.14738/bjhmr.102.14266Keywords:
Therapeutic apheresis, human monoclonal antibodies, non-immunologic diseasesAbstract
Non-immunologic diseases such as nephrological, blood diseases, dyslipoproteinemia, cancer, infections, intoxications etc. have often a severe course or a bad prognosis. Since more than 45 years, therapeutic apheresis has led in combination with other therapies to a steady increase in survival rates. Therapeutic apheresis is indicated in the most of the non-immunologic diseases, and in all antibody-mediated diseases. Since the introduction of hollow fiber membranes, a complete separation of the corpuscular components, pathologic substances, antibodies, toxins etc. is reached. The mortality rate of severe non-immunologic diseases is reduced by therapeutic apheresis. Other new therapies are various human monoclonal antibodies alone or in combination with therapeutic apheresis. The pathological aspects, the first-line and second-lines therapies for non-immunologic such as nephrological, neurological, gastroenterological, hematological diseases, and others are shown. The guidelines of the Apheresis Applications Committee of the American Society for Apheresis are cited. Therapeutic apheresis and/or human monoclonal antibodies have shown to effectively cure severe diseases without immunologic origin.
References
Malchesky PS, Bambauer R, Horiuchi T, Kaplan A, Sakurada Y, Samuelsson. Apheresis Technologies: An International Perspective: Artif Org. 1995; 19(4): 315-323.
Jayne DRW, Gaskin G, Rasmussen N et al. European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18: 2188-2192.
Cascian AL, Jayne DRW, Role of plasma exchange in the treatment of primary vasculitis. Int J Clin Rheumatol. 2010; 5: 339-344.
Yamada Y, Harada M, Hara Y, et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody associated system vasculitis: a systemic review and meta-analysis. Arch Tes Ther. 2012; 23: 141.
Bambauer R, Latza R, Bambauer C, Burgard D, Schiel R. Therapeutic apheresis in autoimmune diseases. Rheumatol Res Rev. 2013; 5:93-103.
Bambauer R, Schiel R. Therapeutic Apheresis and Immunosuppression in Immunologic Diseases. A Review and Own Observation. Clin Immunol Res. 2021; 5(2): 1-36.
Bambauer R. Therapeutic Apheresis in Renal Diseases with Immunologic Origin. Ann Immunol Immunother. 2020; 2: 000114.
Wallukat G, Reinke P, Dörffel WW, et al. Removal of autobodies in dilated cardiopathy by immunoadsorption. Int J Cardiol.1996; 54: 191. PMID: https://www.ncbi.nlm.nih.gov/pubmed/8803685.
Hiepe F, Pfüller B, Wolbart K et al. C1q: multifunctional ligand for a new immunoadsorption treatment. Ther Apher.1999; 3: 246-251: PMID: https://www.ncbi.nlm.nih.gov/pubmed/10427623.epl
Kumlien G, Ullsröm L, Losvall A et al. Clinical experience with a new apheresis filter has specifically detes ABO blood group antibodies. Transfusion 2006; 46: 1568-1575. PMID: https://www.ncbi.nlm.nib.gov/pubmed/16965585.
Bambauer R, Latza R, Burgard D, Schiel R. Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases with Immunologic Origin. Ther Apher Dial. 2016; 20(5): 433-452. Doi 10.1111/1744-9987.12474.
Hafer C, Golla P, Gericke M et al. membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol. 2016; 48:133-138.
Malchesky PS. Membrane processes for plasma separation and plasma fractionation. Guideline Principles for clinical use. Ther Apher.2001; 5: 270-282.
Kaplan AA. Why nephrologists should perform therapeutic plasma exchange. Dial Transplant. 2009;
Madoer F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal disease. J Am Soc Nephrol. 1996;
Bambauer R, Bambauer C, Latza R, Schiel R. Therapeutic apheresis in nephrology. Clin Nephrol Urol Sci. 2014; Doi: 10.72243/2054-7161-1-2.
Schwartz J, Winters JL, Padmanabhan A et al. T Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue. J Clin Apher. 2013; 28: 145-284.
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34: 171-354.
Bambauer R, Schiel R, Lehmann B et al. Therapeutic Apheresis. Technical Aspects. ARPN J Sci Technol. 2012; 2: 339-421.
Bambauer R, Latza R, Schiel R. Therapeutic Plasma Exchange and Selective Plasma Separation Methods. Fundamental Technologies, Pathology and Clinical Results, Fourth Edition, Pabst Science Publishers, D-49525 Lengerich, 2013.
Web S, Dobb G. ARF or ATN or AKI? It´s now acute kidney injury. Anaesth Intensive Care. 2007; 35: 843-
Jörnes A, Frei U. Akutes Nierenversagen. Internist. 2001; 42: 379-403.
Kribben A. Pathogenese des akuten Nierenversagens. Mitt Klin Nephrologie. 2004; XXXIII: 33-34.
Thurau K, Boylan JW. Acute renal success. The unexpected logic of oliguric in acute renal failure. Am J Medicine. 1976; 6: 308-315.
Bambauer R. New Approaches in the Treatment of Acute Kidney Injury. Ther Apher Dial. 2009; 10: 248-
Albuerque P, Meneses G. Toxin-related Acute Kidney Injury. In. Silva Junior GB, Ferreiro Fuentes A, Nangaku M, Remuzzi G, Ronco C (eds.). Nephrology and Public Health Worldwide. Contrib Nephrol. Basel Karger, 2021; 199: 131-142. https://doi.org/10.1159/000517699.
Nalesso F, Stefanelli FC, Di Vico V, et al. The Supporting Role of Combined and Sequential Extracorporeal Blood Purification Therapies in COVID 19 Patients in Intensive Care Unit. Biomedicines 2022; 10(8), 2017; https://doi.org/10.3390/biomedicines10082017.
Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019; 38(3): 295-308, doi:10:23876/j.krcp.10.042.
Bambauer R, Schiel R. Therapeutic Apheresis in Acute Pancreatitis due to Hypertriglyeridemia. Ann Cardiol Cardiovascul Dis. 2017; 2(1): 1014- 1022.
Bardin T, Richette P. Nephrogenic systemic fibrosis, Curr Opin Rheumatol. 2010; 22: 54-58.
Baron PW, Cantos K, Hillebrand DI, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003; 25: 204-209.
Hofmann JC, Reynolds SL, Kiprov DD. Nephrogenic fibrosing dermopathy response to plasma exchange. J Clin Apher. 2005; 20: 12-13.
Gillier M, Cozzio A, Burg G, Nestle FO: Successful treatment of these cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br. J Dermatol. 2005; 152: 531-536.
Poisson JL, Low A, Park YA. The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange. J Clin Apher. 2013; 28: 317-320.
Mathur K, Morris S, Deighan C, et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher. 2008; 23: 144-150.
Zhang R, Rose WN. Photopheresis provides significant long-lasting benefit in nephrogenic systemic fibrosis. Case Rep Dermatol Med. 2017; 3240287.
Bambauer R, Schiel R. Dyslipoproteinemia therapy with lipoprotein-apheresis and/or human monoclonal antibodies. Trends in Medicine. 2019; 19: 1-10.
Ramasamy I. Update on the molecular biology of dyslidemias. Clin Chim Acta. 2016; 454: 143-185.
Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial. 2003; 7:
Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J Am Med Ass. 1996; 276: 882-888.
Schiel R, Bambauer R, Müller U. Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: four year´ experience. Art Organs 1996; 20:318-323.
Bambauer R, Schiel R, Latza R, et al. Treatment of Severe Hyperlipidemia: Six Year ‘Experience with Low-Density Lipoprotein Apheresis. Art Organs. 1996; 20(4): 336-339.
Bambauer R. Low-Density Lipoprotein Apheresis: Clinical Results with Different Methods. Art Organs. 2002; 26(2): 133-139.
Lahere V, Navaaro-Cid J, Ruilope LM. Endothelial dysfunction. Dyslipidemia and atherosclerosis: pathophysiologic and therapeutic implications. Cardio Risk Fact. 1997; 7: 59
Spieker LE, Sudano I, Hurliman D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002; 105: 1399-1402.
Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R. LDL-apheresis technical and clinical aspects. Scientific World Journal. 2012; 314283.
Assmann G, Schulte H, von Eckadstein A. Epidemiological and clinical elevance of triglyceride and high density lipoprotein cholesterol. Cardio Risk Fact. 1995; 5: 4.
Soma MR, Paolett R. The future of cardiovascular disease prevention and the role of lipid regulation. Cardio Risk Fact. 1996; 6: 262-268.
Van BuurenF, Kreikmann S, Horskotte D, et al. HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures. Clin Res Cardiol. (Supplements) 2012; 7:
Ducas J, Siversides C, Dembinski TC. Apoprotein (a) phenotype and lipoprotein (a) level predict eritoneal dialysis patient mortality. Periton Dial Int. 2002; 22:492-499.
Ariyo AA, Thach C, Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003; 349: 2108-2115.
Kanstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Col Cardiol. 2014; 63: 470-477.
Mazhar Z, Hughes A, Garelnabi M. Targeting the Role of Lipoprotein (a) in Stroke. Cardiovasc Hematol Disord Drug Targets. 2017; 17: 64-72.
Kroon AA, Demaker PN, Stalenhoef AF. N-acetylcysteine and serum concentration of lipoprotein (a). J Intern Med. 1991; 230: 519-526.
Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein (a) levels and apolipoprotein (a) inform size on risk of coronary heart disease. J Intern Med. 2014; 276: 260-268.
Roeseler E, Julius U, Heigle F, et al. Lipoprotein apheresis for lipoprotein (a)-associated cardiovascular disease. Prospective 5 years of following-up and apo (a) characterization. Arterioscler Thromb Vasc Biol. 2016; 36: 2019-2027.
Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase trials. J Am Coll Cardiol. 2014; 63: 1278-1288.
Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of Evolocumab for low-density lipoprotein cholesterol reduction. Vascul Health Risk Manag. 2016; 12:163-169.
European Atherosclerosis Society (Study group). Strategies for prevention of coronary heart disease: ma policy statement of the European Atherosclerosis Society. European Heart J. 1990; 8: 77-88.
Yamamoto A, Kawaguchi A, Harada-Shiba M, et al. Apheresis technology for prevention and regression of atherosclerosis: an overview. Ther Apher. (1997); 1: 233-241.
Agishi T, Kaneko J, Hasuo Y, et al. Double filtration plasmapheresis with no or minimal amount of blood derivate for substitution. In: Siebert HG (Ed.). Plasma Exchange. Schattauer, Stuttgart, Germany, 1980, pp. 53-57.
Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low-density lipoprotein in familial hypercholesterolemia. Lancet II,1981; 1005-1007.
Seidel D, Wieland H. Ein neues Verfahren zur selektiven Messung und extrakorporalen Elimination von low-density-Lipoproteinen. J Clin Chem Clin Biochem. 1982; 20: 684-685.
Nosé Y, Usami J, Malchesky PS, et al. Clinical thermofiltration: Initial application. Art Organs. 1985; 9:
Mabuchi H, Michishita J, Mitsuaki T, et al. A new low-density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987; 68: 19-25.
Pokrovsky SN, Adamova IY, Afansieva OY, et al. Immunosorbent for selective removal of lipoprotein(a) from human plasma in vivo study. Art Organs. 1991; 15: 136-140.
Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Art Organs. 1993; 17: 640-652.
Klingel R, Göhlen B, Fassbinder C. Fortschritte der Lipidapherese am Beispiel der membran-Differential-Fitration. Lipidreport 2202; 11: 12-26.
Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, et al. Efficacy and safety of a new whole-blood lowdensity lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Art Organs. 2003;
Kreuzer J, Tiefenbacher C. Atherosklerose. Taschenatlas, Georg Thieme, Stuttgart, 2003
Grossmann M, Rader DJ, Müller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med. 1993; 1: 1148-1154.
Gaudet D, Keriakes DJ, McKenney JM, et al. Effect of Alicocumab, a monoclonal protein convertase subtilisin/Kexin 9 antibody, on lipoprotein(a) concentration (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014; 114: 711-715.
Bambauer R, Schiel R, Latza R. Current topics on low-density lipoprotein apheresis methods. Ther Apher Dial. 2001; 5: 293-300.
Jaeger BR, Seidel D. Hyperlipoproteinemia and LDL apheresis. Clinical expression with the HELP system. Herz 2001; 26:531-544.
Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher. 1997; 1: 242-248.
Bosch T, Lennertz A, Schmidt B, et al. Dali apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoprotein from whole blood. Art Organs. 2000; 24: 81-90.
Moriarty P, Sosland R, Gibson C, Belmont J. Comparison of different low-density lipoprotein apheresis machines on brain natriuretic peptide levels in patients with familial Hypercholesterolemia. Ther Apher Dial. 2010; 14: 74-78.
Abifadel M, Varet M, Rabes JP, et al. Mutations in PCSK9 causes autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156.
Browning JD, Horton JD. Fasting reduces plasma protein convertase subtilisin/kexin type 9 and cholesterol biosynthesis in human. J Lip Res. 2010; 5: 3359-3363.
Lopez D. PCSK9: an enigmatic protease. Biochim Biophys Acta. 2008; 178: 184-191.
Blom DJ, Dent R, Castro RC, Toth PP PCSK9 inhibition in the management of hyperlipidemia focus on evolocumab. Vasc Health Risk Manag. 2016; 12: 185-197. th
Murphy K, Travers P, Walport M. Janeway´s immunology. 7 ed. Garland Science, Taylor and Francis Group, New York, 2008.
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93: 2645-2668.
Moriatry PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: ODYSEY ESCAPE trial. Eur Heart J. 201^6; 37: 3588-
Sabatine MS, Leiter LA, Wiviott SD. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prescribed analysis of the FOURIER randomized trial. Lancet Diabetes Endocrinol. 2017; 5:
Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of Evolocumab for low-density lipoprotein cholesterol reduction. Vascul Health Risk Manag. 2016; 12.: 163-169.
Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005; 36: 3-10.
Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005; 23:1117-1125.
Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol. 2008; 20: 450-459.
Stoekebroek RM, Hartgens ML, Rute R, et al. PCSK9 inhibitors in clinical practice: Delivering on the promise? Atherosclerosis. 2018; 270: 205-210.
Karatasakis A, Danek B, Karacsonyi J. The effect of proprotein convertase subtilisin-kexin Type 9 inhibitors on clinical outcomes in patient with hypercholesterolemia: A meta-analysis of 16,721 patients from 33 randomized clinical trials. J Am Col Cardiol. 2017; 69:
Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 143) in heterozygous familial hypercholesterolemia (RUTHER-FORD-2): a randomized, double-blind, placebo-controlled trial. Lancet 2015; 385: 331-340.
Groß E, Hohenstein B, Julius U. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. Atheroscler Suppl. 2015; 18: 226-232.
Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017; 376: 41-51.
Rader DJ, Kastelein IJ. Lomitapide and mipomersen: two first -in-class drugs for reducing low-densitylipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2015;
Grossmann M, Rader DJ, Müller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med. 2015; 1: 1148-1154.
Bambauer R, Schiel R, Keller, HE, Latza R. LDL-apheresis in two patients with extremely elevated lipoprotein (a) levels. Int J Artif Organs. 1995; 18(5): 286-290.
Bambauer R, Schiel R, Latza R. Current Topics on Low-Density Lipoprotein Apheresis. Ther Apher. 2001; 5(4): 293-300.
Bambauer R. Low-Density Lipoprotein Apheresis: Clinical Results with Different Methods. Artif. Organs. 2002; 26(2): 133-139.
Wang A, Richhariya A, Gandra SR, et al. Systematic Review of Low-Density Lipoprotein Apheresis for the Treatment of Familial Hypercholesterolemia. J Am Heart Assoc. 2016; 5(7): e003294. Doi:10.1161/JAHA.116.003294.
Thompson G, Parhofer G. Current Role of Lipoprotein Apheresis. Curr Atheroscler Rep. 2019; 21(7): 28. Doi:10.1007/s11883-019-0787-5.
Safarova MS, Nugent AK, Gorby L, et al. Effect of Lipoprotein Apheresis on Progression of Carotid Intima-Media Thickness in Patients with Severe hypercholesterolemia. Am J Cardiol. 2022; 177: 22-27.
Jatem E, Lima J, Monmtoro B, et al. Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated with Refractory Nephrotic Syndrome. Kid Int Rep. 2021; 6(1): 101-109.
Torres E, Goicoechea M, Hernández A, et al. Efficacy of Evoloocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). J Clin Apher. 2021; 35(1): 9-17.
Raal GJ, Rosenson RS, Reeskamp L, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 383: 711-720.
Saotme T, Endo Y, Saaki T, et al. A case of severe acute pancreatitis treated with CTR-001 direct Hemoperfusion for Cytokine Apheresis. Ther Apher. 2005; 9: 367-371.
Mao EQ, Tang YO, Zang SD. Formalized therapeutic guidelines for hyperlipidemic severe acute pancreatitis. World J Gastroenterol. 2003; 9: 2622-2626.
Gubensek J, Buturovic-Ponikvar J, Romozi K, et al. factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study. PloS One. 2014; 9: e102748.
Stefanutti C. Therapeutic Plasmapheresis. A gate to an Effective Treatment of Severe pathological Conditions. Adv Biosc Clin Med. 2014; 2: 1-3.
Campos A, Santos J, Freitas C, et al. Plasmapheresis in the management of Acute Pancreatitis due to Severe Hypertriglyceridemia-Reporting New Cases. J Renal hepatitis Dis. 2017; 1: 29-34.
Nasa P, Alexander G, Kulkami A, et al. Early plasmapheresis in patients with severe hypertriglyceridemia induced acute pancreatitis. Indian J Crit Care Med. 2015; 19: 487-489.
Bambauer R, Marquart U. Therapeutic Plasma Exchange in the Treatment of Acute hepatic Failure. In: Agishi T et al. (Eds.), Therapeutic Plasmapheresis (XII), VSP.1993, pp. 197-200.
Bambauer R, Bambauer C, Burgard D, Schiel Ralf. Therapeutic Apheresis and other Artificial Liver Support Systems in Liver Diseases: Technical and Clinical Aspects. In: Konstandin K (Ed.), Apheresis. Nova Science Publishers. 2014.
Jalan R, Gines P, Olson JC, et al. Acute-on-chronic liver failure. J Hepatol. 2012; 57(6): 1336-1348.
Lie TS. Treatment of acute hepatic failure by extracorporeal perfusion over baboon or human liver. In: Chang TMS (ed.), Artificial Kidney, artificial liver, artificial cells. Plenum Press, New York, 1978, pp: 105-
Lepore MJ, Martell AJ. Plasmapheresis with plasm exchange in hepatic coma. Methods and results with acute fulminate necrosis. Ann Intern Med. 1970; 72: 165-174.
Ash SR, Steczko J, Knab WR et al. Push-pull sorbent-based pheresis and hemodiabsorption. Ther Apher. 2000; 4: 218-228.
Falkenhagen D, Strobel W, Vogt G, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs: 1999; 23: 81-86.
Stange J, Mitzner SR, Rilser T, et al. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial Liver support. Artif Organs. 1999; 23:319-321.
Detry O, De Roover A, Honoré P. Brain edema and intracranial hypertension in fulminant hepatic failure. Pathophysiology and management. W J Gastroenterol. 2006; 12: 7405-7412.
Nosé Y. Artificial Liver for a bridge to liver transplantation. Artif Organs. 1989; 13: 415.
Chris-Olaiya A, Kapoor A, Ricci KS, et al. Therapeutic plasma exchange in liver Failure. World J Hepatol. 2021; 13(8): 904-915.
Ewn K, Chun S, Kim NJ, et al. Initial experience with high-volume plasma exchange in patients with acute liver failure. J Clin Apher. 2021; 36(3): 379-389.
Pagano MB, Hobbs W, Linenberger M, et al. Plasma and red cell exchange transfusions for erythropoietic protoporphyria: a case report and review of the literature. J Clin Apher. 2012;M 27: 336-341.
Pham HP, Schwartz J, Tanhehco Y. Therapeutic plasma exchange in a patient with erytrpoietic protoporphyria status post orthotopic liver transplantation as a bridge to hematopoietic stem cell transplantation. J Clin Apher. 2014; 29:341-342.
Spiva DA, Lewis CE. Erythropoietic protoporphyria: therapeutic response to combined erythrocyte exchange and plasmapheresis. Photodermatol 1984; 1: 211-220.
Frankovich J, Swedo SE, Murphy TK, et al. Clinical Management of Pediatric Acute-onset Neuropsychiatric Syndrome: Part II-Use of Immunodulatory Therapies. J Child Adolesc Psychopharma. 2017; 27(7): 1-16.
Hagermann RJ, Hall DA, Coffey S, et al. Treatment of fragile x-associated tremor ataxia syndrome (FX-TAS) and related neurological problems. Clin Interv Aging. 2008; 3: 251-262.
Verny C, Prundean A, Nicolas G, et al. Refsum´s disease may mimic familial Guillain-Barré syndrome. Neuromusc Dis. 2006; 16: 803-808.
Wills AJ, Maning NJ, Reilly MM. Refsum´s disease. Q J Med. 2001; 94: 403-406.
Straube R, Gäckel D, Thiele A, et al. Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome – an update of treatment modalities and pathophysiological cognition. Transfus Apher Sci. 2003; 29: 85-91.
Wegrzyn AB, Herzog K, Gerding A, et al. Fibroblast-specific genome-scale modelling an imbalance in amine acid metabolism in Refsum disease. FFBS J. 2020.
Stepien KM, Wierzbicki AS, Pollthe BT, et al. Challenges of a Successful Pregnancy in a Patient with Adult Refsum´s Disease due to Phytanoyl-CoA Hydrolase Deficiency. In: Morava E, Baumgartner M, Patterson M, et al. (Eds.), JIMD Reports. 2016, Vol. 33, Springer, Heidelberg.
Muchtat E, Dispenzierl H, Magen M, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2020; 289(3): 268-292.
Gejyo F, Amano I, Ando T, et al. Society of β2-Microglobulin Adsorption Therapy: Survey of the effects of a column for adsorption of β2-microglobulin inpatients with dialysis-related amyloidosis in Japan. Ther Apher Dial. 2013; 17: 40-47.
Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light chain amyloiddosis. J Clin Oncol. 2020; 38(28): 3252-3260.
Kastritis E, Palladini G, Minnema M, et al. Subcutaneous daratumumab + cyclophosphamide, bortzomib, and dexamethasone (CYBORD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. EHA Library, 2020 Abstract LB2604.
Moser HW, Lorenz´s oil. Lancet1993; 341-344.
Moser HW, Naidu S, Kumar AJ, et al.. The adrenoleukodystrophies. Crit Rev Neurobiol. 1987; 3: 29-88.
Mosser J, Dounar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature;1993:361-726-730.
3Lazo O, Contreras M, Hashimi M, et al. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA 1988;85:7647-7651.
Wanders RJ, van Roermund CW, van Wijland, et al. X-linked adrenoleukodystrophy: Identification of the primary defect od a deficient peroximal very long chain fatty acyl-CoA synthetase using a new developed method for isolation of peroxisomes from skin fibroblasts. J Inherited Metab Dis. 1988; 11: 1^73-177.
Moser HW, Moser AB, Smith KD, et al. Adrenoleukodystrophy: Phenotype variability and implications for therapy. J Inherted Metab Dis. 1992; 15: 643-664.
Moser Ab, Borel J, Odone A, et al. A new dietary therapy for adrenoleukodystrophy; Biochemical and preliminary clinical results in 36 patients. Ann Neiurol. 1987: 21: 240-249.
Rizzo WB, Phillips MW, Damman AL, et al. Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels. Ann Neurol. 1987: 21:232-239.
Rizzo WB, Leshner RT, Odone A, et al. Dietary erusic and therapy for X-linked adrenoleukodystrophy: Neurology, 1989; 39: 1415-1422.
Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic acid and erucic acid (Lorenzo´s oil) as treatment for adrenoleukodystrophy. N Engl J Med. 1993; 329: 745-752.
Kaplan PW, Tusa RJ, Shrankroff J, et al. Visual evoked potentials in adrenoleukdystrophy. A trial with glycerol trioleate and Lorenzo´s oil: Ann Neurol. 1993; 34: 169-174.
Maeda K, Suzuki Y, Yajima S, et al. Imptovement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy. Brain Dev. 1992; 14: 409-412.
Korenke OC, Hunnemann DH, Kohler J, et al. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyelo-neuropathy. Effect on clinical biochemical and neurophysiological parameters. Eur J Pediatr. 1995; 154: 64-70.
Bambauer R, Shiel R, Cordes H, et al. Plasmapheresis in Treatment of Adrenoleukodystrophy. Ther Apher. 1997; 1(2): 152-154.
Moser HW, Moser AB, Frayer KK, et al. Adrenleukodystrophy: Increased plasma content of satured very long chain fatty acids. Neurology 1981; 31: 1241-1249.
Ma CY, Li C, Zhou X, et al. Management of adrenoleukodystrophy: From pre-clincal studies to the development of new therapies. Biome Pharmacother. 2021: 112214.
Engelen M, van Ballegoij WJC, Mallavck EJ, et al. International Revcommendations fort the Diagnosis and management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology, Contemo Issues Pract Educat Res. 2022. Doi: https://doi.org/10.1212/WNL.0000000000201374.
Buzzenti E, Kalafatelli M, Thorburn D, et al. Interventions for hereditary haemochromatosis: an attemptted network meta-analysis. Cochrane Database syst Rev. 2017: (3): CDOI 1647.
Fernandez-Mosteirin N, Salvador-Osuna C, Garcia-Erce JA, et al. Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations. Med Clin. 2006; 127: 409-
Rombout-Sestrienkova E, Winkens B, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial. Transfusion 2016; 56: 261-270.
Sundic T, Hervig T, Hannisdal S, et al. Erythrocytapheresis compared with whole phlebotomy for the treatment of hereditary hemochromatosis. Blood Transf, 2014; 12: s84-s89.
Rombout-Sestrienkova E, Brandts L, Koek GH, et al. Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytapheresis than with phlebotomies. J Clin Apher. 2021; 37(1): 100-105. https://doi.org/10.1002/jca.21956.
Miyamoto Y, Hamasaki Y, Matsumoto A, et al. Prediction of immunoglobulin M reduction via simple dose of therapeutic plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenström macroglobulin. J Clin Apher. 2018; 33:611-
Datta SS, Mukherjee S, Talukder B, et al. Immunoglobulin M “flare” seen in a case of Waldensröm macroglobulinemia successfully managed by therapeutic plasma exchange. Indian J Hematol Blood Transfus. 2016; 32: 208-210.
Merz T, Marchesoni I, Caminit G, et al. Efficacy of plasmapheresis as treatment for bilateral hyperviscosity syndrome related retinopathy in multiple myeloma. Eur J Ophthalmol. 2022: 32(4): NP48-NP51. Doi:10.1177/1120672121997069.
Dimopoulos MAI, Gracia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldensröm macrogolbulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood; 122: 3276-3378.
Kastritis E, Kyrtsonis MC, Morel P, et al. Competing risk survival analysis in patients with symptomatic Waldenström Macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haemtologica 2015; 100: e446-e449.
Lokhandwala PM, Shabikhani M, Ness PM, Bloch EM. Therapeutic plasma exchange for hyperviscosity syndrome secondary to high rheumatoid factor. Transfus Apher Sci. 2018; 57(2): 225-227.
Kalpakci Y, Hacibekiroglu T, Darcin T, et al. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey. Transfus Apher Sci. 2021; 60(5):103244.
Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet. 2012; 379:1728-1738.
Pulido JS, Winters JL, Boyer D. Preliominary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Opth6thalmol Soc. 2006; 104: 221-231.
Klingel R, Fassbender C, Heibges A, et al. RheoNet registry analysis of rheopheresis for microcirculation disorders with a focus on age-related macular degeneration. Ther Apher Dial. 2010; 14: 276-286.
Blaha M, Renova E, Langrova H, et al. Rheohaemapheresis in the treatment of nonvascular macular degeneration. Atheroschler Suppl. 2013; 14: 179-184.
Finger RP, Krohne TU, Charbel Issa P, et al. Plasmapheresis for dry age-related macular degenerationevidence based? Retina. 2009; 29:569-572.
Waugh N, Loveman E, Colquit J, et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systemic review: Southampton (UK): NIHR Journals Library; 2018 May, (Health Technology Assessment, No. 22.27), 2022.
Randmann O, Weiss KH, Kaler SG. Wilson´s disease and other neurological copper disorders. Lancet Neurol. 2015; 14: 103-113.
Chiu A, Tsoi NS, Fan ST. Use of the molecular absorbents recirculating system as a treatment for acute decompensated Wilson disease. Liver Transpl. 2008; 14: 1512-1516.
Weiss KH, Askari FK, Czlonkowski A, et al. Bis-tetrathio,molybdate in patients with Wilson´s disease: an open-label, multicenter, phase 2 study. Lancet Gastroenterol Hepatol. 2017; 2: 869-876.
Akyildiz BN, Yildirim S, Kondolor M. Arslan D. Is plasma exchange effective in prevention of hepatic transplantation in fulminant Wilson disease with hepatic failure. J Pediatr Gasterenterol. 2011; 52: 778-
Asfaha S, Almansori M, Qarni U, Gutfreund KS. Plasmapheresis for hemolytic crisis and impending acute liver failure in Wilson disease. J Clin Apher. 2007; 22: 295-1298.
Pawaria A, Sood V, Bihari B, et al. Ninety days transplant free survival with high volume plasma exchange in Wilson disease presenting as acute liver failure. J Clin Apher. 2020; 36(1): 109-117.
Yu Z, Wu R, Wu M, et al. Preparation of polyamine-functionalized copper specific adsorbents for selective adsorption of copper. Col Surf B: Biointerfaces 2010; 78(2): 222-228.
Foss FM, Giradi M. Mycosis fungoides and Sézary syndrome. Hematol Oncol Clin North Am. 2017; 31:
Wilcox RA. Cutaneous T-cell lymphoma: 201^6 update on diagnostic, risk-stratification, and management. Am J Hematol. 2016; 91: 151-165.
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Tresatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer. 2017; 77: 57-74.
Alfred A, Taylor PC, Dignan F, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement up-date from the UK Photopheresis Society. Br J Hematol. 2017; 177: 287-310.
Atilla E, Atilla PA, Bozdag SC, et al. Extracorporeal photochemotherapy in mycosis fungoides. Transfus Clin Biol. 2017; 24: 454-457.
Sanyal S, Child F, Alfred A, et al. UK national of extracorporeal photopheresis in cutaneous T-cell lymphoma. Br J Dermatol. 2018; 178: 569-570.
Siegenthaler N, Giraud R, Bendjelid K. Erythrocytapheresis and sublingual micro-vascular flow in severe malaria. Clin Hemorheol Microcirc. 2010; 46: 299-304.
Schutt RC, Ronco C, Rosner MH. The role of therapeutic plasma exchange in poisonings and intoxications. Semin Dial. 2012; 25: 201-206.
Disel NK, Akpinar AA; Sebe A, et al. Therapeutic plasma exchange in poisoning: 8 years´ experience of a university hospital: Am J Emerg Med. 2015; 33:_ 1391-1395.
Geith S, Renner B, Rabe C, et al. Ibuprofen plasma concentration profile in deliberate ibuprofen overdose with circulatory depression treated with therapeutic plasma exchange: a case report: BMC Pharmacol Toxicol. 2017; 18: 81.
Ibrahim RB, Balogun RA. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial. 2012; 25: 176-189. th
Seyffart G. Poison Index. The treatment of acute intoxication. 4 Edition, Pabst Sciences Publishers, Lengerich, Berlin, Düsseldorf, Leipzig, Riga, Scottsdale, Wien, Zagreb, 1997.
Cardoso C, Coelho S. Extracorporeal Treatment for Poisoning. Port Nephrol Hypert. 2022; 36(3): 148-
Bambauer R, Schiel R. Therapepeutic Apjheresis and Immunosuppression in Immunologic Diseases: A Review and Own Observations. Clin Immunol Res. 2021; 5(2): 1-36
Bambauer R, Schiel R, Salgado OJ. Therapeutic Apheresis, Immunosuppression and Human Monoclonal Antibodies in Hematologic diseases most with immunologic origin. Medical Research Archives (online) 2022; 10(10. https://doi.ora/10.18103/mro.v1Oil0.3147.
Malchesky PS. Therapeutic Apheresis: Why? Ther Apher Dial. 2015; 19: 417-426
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rolf Bambauer, Ralf Schiel, Octavio S Salgado
This work is licensed under a Creative Commons Attribution 4.0 International License.
